Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orca-T in Advanced Hematologic Malignancies
NCT04013685Phase 1Active, not recruiting
- Sponsor
- Orca Bio
- Start
- Nov 2019
- Primary completion
- Apr 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of regulatory T-cell enriched infusion in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and 2 more, sponsored by Orca Bio. Primary endpoints: Incidence of primary graft failure at 365 days and Incidence of grade 3 or 4 acute Graft-Versus-Host Disease at 180 days. Started Nov 2019; status: active, not recruiting.
02
Drugs
regulatory T-cell enriched infusion
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04013685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013685.